Added to YB: 2024-06-28
Pitch date: 2024-04-10
LEGN [bullish]
Legend Biotech Corporation
-60.34%
current return
Author Info
No bio for this author
Company Info
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
Market Cap
$5.6B
Pitch Price
$55.50
Price Target
N/A
Dividend
N/A
EV/EBITDA
-29.95
P/E
-23.25
EV/Sales
5.51
Sector
Biotechnology
Category
growth
TimesSquare Capital U.S. FOCUS Growth New Position: Legend Biotech Corporation
LEGN: Biotech dev cell therapies for blood cancers. EU & FDA approved Carvykti for multiple myeloma. Stock down on production ramp-up concerns. Long-term growth potential w/ J&J agreement & Novartis partnership. Initiated position despite short-term production worries, seeing extended growth runway ahead.
Read full article (1 min)